| First Author | Reay DP | Year | 2011 |
| Journal | Neurobiol Dis | Volume | 43 |
| Issue | 3 | Pages | 598-608 |
| PubMed ID | 21624467 | Mgi Jnum | J:173320 |
| Mgi Id | MGI:5013861 | Doi | 10.1016/j.nbd.2011.05.008 |
| Citation | Reay DP, et al. (2011) Systemic delivery of NEMO binding domain/IKKgamma inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis 43(3):598-608 |
| abstractText | The activation of nuclear factor kappaB (NF-kappaB) contributes to muscle degeneration that results from dystrophin deficiency in human Duchenne muscular dystrophy (DMD) and in the mdx mouse. In dystrophic muscle, NF-kappaB participates in inflammation and failure of muscle regeneration. Peptides containing the NF-kappaB Essential Modulator (NEMO) binding domain (NBD) disrupt the IkappaB kinase complex, thus blocking NF-kappaB activation. The NBD peptide, which is linked to a protein transduction domain to achieve in vivo peptide delivery to muscle tissue, was systemically delivered to mdx mice for 4 or 7 weeks to study NF-kappaB activation, histological changes in hind limb and diaphragm muscle and ex vivo function of diaphragm muscle. Decreased NF-kappaB activation, decreased necrosis and increased regeneration were observed in hind limb and diaphragm muscle in mdx mice treated systemically with NBD peptide, as compared to control mdx mice. NBD peptide treatment resulted in improved generation of specific force and greater resistance to lengthening activations in diaphragm muscle ex vivo. Together these data support the potential of NBD peptides for the treatment of DMD by modulating dystrophic pathways in muscle that are downstream of dystrophin deficiency. |
